Dynacure Company

Dynacure is initially focused on developing treatments for neuromuscular diseases, beginning with myotubular and centronuclear myopathies, or CNM. Our lead product candidate, DYN101, is an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of CNM patients.

Headquarters: France
Industry: Loss of Proteostasis